On Thursday night, Feb. 26, at midnight, the Las Vegas Strip welcomed its newest outdoor entertainment spectacle: the Swarovski Midnight Celebration at Grand Bazaar Shops. Created for Swarovski’s custom pavilion and six-story-tall Starburst, the Swarovski Midnight Celebration was designed to be the centerpiece of the new Grand Bazaar Shops, providing a unique retail and entertainment experience.
The Swarovski Midnight Celebration is a dazzling three-minute-long light-and-sound show designed to mark the dawn of a new day. The spectacle was envisioned as a way to bring New Year’s Eve-style excitement to the Strip every night of the year. The production incorporates the Swarovski Starburst—a one-of-a-kind, 14-foot-diameter structure composed of 911 custom-cut Swarovski crystal spheres—as well as a large video screen embedded into the multi-faceted façade of the Swarovski pavilion. Evocative scenes from exotic bazaars, together with the Starburst’s more than 1,800 points of LED light, are choreographed to a dramatic original score featuring enchanting beats of world music.
To view the Multimedia News Release, go to http://www.multivu.com/players/English/7437751-swarovski-midnight-celebration/
The Toyota Prius v is the only midsize car out of 31 evaluated to earn a good rating in the Insurance Institute for Highway Safety’s first-ever headlight ratings.
The best available headlights on 11 cars earn an acceptable rating, while nine only reach a marginal rating. Ten of the vehicles can’t be purchased with anything other than poor-rated headlights.
A vehicle’s price tag is no guarantee of decent headlights. Many of the poor-rated headlights belong to luxury vehicles.
The ability to see the road ahead, along with any pedestrians, bicyclists or obstacles, is an obvious essential for drivers. However, government standards for headlights, based on laboratory tests, allow huge variation in the amount of illumination that headlights provide in actual on-road driving. With about half of traffic deaths occurring either in the dark or in dawn or dusk conditions, improved headlights have the potential to bring about substantial reductions in fatalities.
Not a single small SUV out of 21 tested earns a good rating in the Insurance Institute for Highway Safety’s headlight evaluations, and only four are available with acceptable-rated headlights.
Among the 21 vehicles, there are 47 different headlight combinations available. More than two-thirds of them are rated poor, making this group of vehicles even more deficient when it comes to lighting than the midsize cars that were the first to be rated earlier this year.
Headlight performance in today’s vehicles varies widely. Government standards are based on laboratory tests, which don’t accurately gauge performance in real-world driving. The issue merits attention because about half of traffic deaths occur either in the dark or around dawn or dusk.
As with midsize cars, the IIHS evaluations of small SUVs showed that a vehicle’s price tag doesn’t correspond to the quality of headlights. More modern lighting types, including high-intensity discharge (HID) and LED lamps, and curve-adaptive systems, which swivel in the direction of steering, also are no guarantee of good performance.
Federally funded research that provides a deep understanding of cancer is spurring advances against many types of the disease. With a strong bipartisan commitment from Congress to keep investment in biomedical research a national priority, we can accelerate our pace of progress and save more lives from cancer, according to the seventh annual American Association for Cancer Research (AACR) Cancer Progress Report, released today.
Basic research in the fields of immunology and cancer genetics has recently been harnessed to develop two new forms of cancer treatment: immunotherapy and precision medicine. As detailed in the report, the utility of these treatments is expanding rapidly. In May 2017, the U.S. Food and Drug Administration (FDA) heralded a new dawn for precision medicine when it approved the immunotherapeutic pembrolizumab (Keytruda) for treating patients with any solid tumor harboring specific genetic characteristics. This is the first anticancer therapeutic approved based on cancer biomarkers rather than the location in the body where the cancer originated.
To view the multimedia release go to:
https://www.multivu.com/players/English/8155051-aacr-cancer-progress-report-2017/
